



A Prospective Study of Pharmaceutical Care for Lymphoma Patients in the Department of Oncology, Nishtar Hospital, Multan, Pakistan

Naveed NISAR ^{1,2}, Mehboob-e-RABBANI ¹, Ahmad I. MASOOD ²,
Sadia BASHIR ³, Sabiha KARIM ⁴ & Ghulam MURTAZA ^{5*}

¹ Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan.

² Department of Clinical Oncology,

³ Department of Gynaecology and Obstetrics, Nishtar Hospital, Multan, Pakistan.

⁴ University College of Pharmacy, The University of Punjab, Lahore, Pakistan.

⁵ Department of Pharmaceutical Sciences, COMSATS Institute of Information Technology,
Abbottabad 22060, Pakistan.

SUMMARY. To evaluate the pharmaceutical care of lymphoma patients, a prospective, descriptive study was carried out in the Department of Oncology, Nishtar hospital, Multan, Pakistan, involving a total of 70 lymphoma patients from 11 to 70 years of age. Patients were divided into 7 cohorts of 10 each and were monitored using pharmaceutical care indicators using the WHO's method. Percentage of patients diagnosed as Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) was 45.71 and 54.29 %, respectively and the results are significantly ($p < 0.05$) different. Stage-wise diagnosis of lymphoma patients (%) at stage I, II, III, and IV were 10, 24.3, 34.3, and 31.4 %, respectively, and these results are significantly ($p < 0.05$) different. Percentage of patients reported with B-symptoms at stage I and II was 7 % while at stage III and IV was 44 % in HD, and in indolent lymphoma was 10 % and in aggressive lymphoma was 25 % in NHL. Out of 38 NHL patients, one received R-CHOP treatment whereas, remaining 37 patients received only CHOP treatment. If pharmacist checks all the prescriptions, maintain pharmaceutical care plan including follow up plan of all patients under SOAP format and implement guidelines of Standard Pharmaceutical Care Plan, the management of lymphoma can be improved.

KEY WORDS: Hodgkin's disease, Lymphoma, Management, Non-Hodgkin's lymphoma, Pharmaceutical care.

* Author to whom correspondence should be addressed. E-mail: gmdogar356@gmail.com